We first chose to test a well‐established p53‐positive HR+ breast cancer line, MCF7, which we verified could hold a prolonged arrest for up to 7 days following 1 μM palbociclib treatment (Fig EV4A). This evidence concerns the gene TP53 and breast cancer.